ArticleGenetics and molecular biology2026
Assessment of the bacterial community of the human upper respiratory tract in patients affected by Covid-19.
Article in Genetics and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the challenges posed by the 2019 coronavirus disease (COVID-19), understanding the role of the microbiota is crucial. The analysis of this microbial community in the body not only expands our understanding of health, but also provides insights into the interaction between viruses, microbiota, and the human host. In this study, we aimed to identify possible variations in bacterial diversity caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The study involved 45 volunteers, divided into the Positive Group (PG) consisting of 14 patients and the Negative Group (NG) consisting of 31 individuals. Both groups were stratified by biological sex to ensure sample homogeneity. Samples were collected using nasopharyngeal and oropharyngeal swabs, and total DNA was extracted and stored. The V4 region of the 16S rRNA gene was sequenced, and bioinformatics tools were used to assess the composition and diversity of the respiratory microbiota. In our results, the most abundant bacterial phyla were: Firmicutes, Bacteroidetes, and Proteobacteria. There was a notable reduction in the frequency of Firmicutes in the PG, suggesting a potential compromise in the immune response to viral infection. Beta diversity analysis did not reveal significant variations between the communities of the groups. Additionally, the analysis indicated subtle changes in some taxa, such as an increase in the abundance of Neisseriaceae in patients affected by COVID-19. These findings contribute to a deeper understanding of the complex interaction between the virus, the microbiota, and the host during infection with SARS-CoV-2, highlighting the importance of the respiratory microbiota in the context of COVID-19.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.